The combination consist of chlorpheniramine, dextromethorphan, and phenylephrine which shows synergistic action used to treat cough, runny or stuffy nose, sneezing, itching, and watery eyes caused by allergies, the common cold, or the flu. Dextromethorphan is a cough suppressant. It affects the signals in the brain that trigger cough reflex. Chlorpheniramine is an antihistamine that reduces the effects of natural chemical histamine in the body as histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose. Phenylephrine is a medication primarily used as a decongestant to provide relief from blocked nose. Cough that is caused by smoking, asthma, or emphysema will not be treated by this syrup.
Each 5 ml contains:
Dextromethorphan IP 10 mg
Phenylephrine HCl IP 5 mg
CPM (Chlorphenamine maleate) IP 2 mg
Syrup
For Cough
Coughs and upper respiratory tract symptoms, Nasal congestion, and Allergy or common cold.
Dextromethorphan suppresses medullary cough center and is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate). It acts as a non-competitive channel blocker and is one of the widely used antitussives. It is also used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan is categorized as an opioid drug that acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors. It is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. It is rapidly absorbed from GIT and is extensively metabolised to dextrorphan (active metabolite) in liver. The half-life is 3-6 hours.
Chlorphenamine maleate is a H1 receptor antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is well orally absorbed with a plasma protein binding of 72%. It is metabolised in liver with a half-life of 21-27 hours.
Phenylephrine is categorized as sympathomimetic drug and mimics the actions of epinephrine (commonly known as adrenaline) or norepinephrine. Phenylephrine selectively binds to alpha-1 receptors which cause blood vessels to constrict leads to nasal decongestant action. When orally administered, the bioavailability was found to be 38%. Peak concentration reaches between 0.5 and 2 hours after administration. No protein‐binding data in humans are available. It undergoes extensive biotransformation in the gut wall and the liver. Half‐lives is relatively short, approximately 2.5 hours. Reduced metabolism of Phenylephrine occurs with concurrent administration of monoamine oxidase inhibitors.
The product is possible safe for most adults. There is no disadvantage associated with the product if taken under the recommended usage however blurred vision, dry mouth, nausea, stomach pain, constipation, skin rashes or itching can occur in some patients.